AI assistant
AGIOS PHARMACEUTICALS, INC. — Director's Dealing 2018
Aug 10, 2018
31580_dirs_2018-08-10_6abebaca-2255-4ec8-8fd1-31f7fb54d3aa.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4/A — Form 4/A
Issuer: AGIOS PHARMACEUTICALS INC (AGIO)
CIK: 0001439222
Period of Report: 2018-05-23
Reporting Person: Biller Scott (Chief Scientific Officer)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2018-05-23 | Stock option (right to buy) | $31.64 | M | 15177 | Disposed | 2024-03-04 | Common stock (15177) | Direct |
Footnotes
F1: This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
F2: The original Form 4 stated that derivative securities were acquired as a result of the transaction, when in fact the transaction was a disposition of derivative securities. This Form 4 amendment is solely to correct the nature of the transaction.
F3: This option was granted on March 5, 2014. The shares underlying this option vest as to 25% of the shares on March 5, 2015, with the remaining 75% vesting in 36 equal monthly installments thereafter.